Ekso Bionics (NASDAQ:EKSO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note released on Sunday morning. The brokerage issued a hold rating on the stock.

A number of other research firms have also recently commented on EKSO. Lake Street Capital dropped their price objective on Ekso Bionics from $2.00 to $1.00 and set a “buy” rating on the stock in a research note on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and set a $9.00 target price on shares of Ekso Bionics in a research report on Tuesday, March 4th.

Ekso Bionics Stock Performance

EKSO stock opened at $0.40 on Friday. Ekso Bionics has a 1-year low of $0.34 and a 1-year high of $1.53. The company has a current ratio of 2.81, a quick ratio of 2.14 and a debt-to-equity ratio of 0.28. The stock has a 50-day moving average price of $0.45 and a 200-day moving average price of $0.64. The firm has a market cap of $11.69 million, a PE ratio of -0.62 and a beta of 1.33.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.07). The firm had revenue of $5.09 million during the quarter, compared to analyst estimates of $5.05 million. Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. As a group, equities research analysts expect that Ekso Bionics will post -0.48 earnings per share for the current year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.